Deposition of C3, the terminal complement complex and vitronectin in primary biliary cirrhosis and primary sclerosing cholangitis.

Characteristics of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) are bile duct destruction and portal inflammation. Increased levels of circulating complement activation products are also present. This raises the possibility of involvement of complement-dependent cytotoxic mechanisms in the pathogenesis. Therefore, we investigated liver biopsy specimens from 21 patients with PBC, six patients with PSC and six controls for complement deposits by immunohistochemistry using polyclonal and monoclonal antibodies against C3d, the terminal complement complex (TCC) and vitronectin (S-protein). We found C3d, TCC and vitronectin deposits only in the portal tracts. C3d and TCC were present in the walls of the hepatic arteries and in the connective tissue stroma but never around the bile ducts. We found vitronectin deposits throughout the connective tissue, often independent of the TCC deposits. When vitronectin and TCC were co-localized, the staining patterns were inverse; that is, intense staining for TCC accompanied weak staining for vitronectin and vice versa. Occasionally complete dissociation between TCC and vitronectin staining was observed. Deposits of TCC and vitronectin showed a focal distribution leaving many portal tracts free of TCC. Our results question whether complement-dependent cytotoxic mechanisms take part in the bile duct destruction in PBC and PSC.

[1]  S. Meri,et al.  Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[2]  S. Bhakdi,et al.  Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions , 1990, The Journal of experimental medicine.

[3]  S. Bhakdi,et al.  [Functions and relevance of the terminal complement sequence]. , 1990, Immunitat und Infektion.

[4]  Francesco Saverio Tedesco,et al.  Immunohistochemical detection of terminal complement complex and S protein in normal and pre‐eclamptic placentae , 1990, Clinical and experimental immunology.

[5]  T. Halstensen,et al.  Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis. , 1990, Gastroenterology.

[6]  H. Stein,et al.  Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. , 1990, Journal of clinical pathology.

[7]  P. Garred,et al.  C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes. , 1990, Journal of immunology.

[8]  D. Vergani,et al.  Activation of the complement system in primary sclerosing cholangitis. , 1989, Gastroenterology.

[9]  P. Hudson,et al.  Molecular cloning and characterization of the novel, human complement‐associated protein, SP‐40,40: a link between the complement and reproductive systems. , 1989, The EMBO journal.

[10]  T. Halstensen,et al.  Deposits of terminal complement complex (TCC) in muscularis mucosae and submucosal vessels in ulcerative colitis and Crohn's disease of the colon. , 1989, Gut.

[11]  K. Preissner,et al.  Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes. , 1988, Clinical and experimental immunology.

[12]  T. Halstensen,et al.  Terminal complement complex (TCC) and S-protein (vitronectin) on follicular dendritic cells in human lymphoid tissues. , 1988, Immunology.

[13]  M. Harboe,et al.  Immunohistochemical Detection of the Membrane and Fluid‐phase Terminal Complement Complexes C5b‐9(m) and SC5b‐9 , 1987, Scandinavian journal of immunology.

[14]  D. Mathey,et al.  Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. , 1986, Journal of immunology.

[15]  J. Hoofnagle,et al.  Anticomplement receptor activity in the serum of patients with primary biliary cirrhosis. , 1986, Gut.

[16]  D. Jenne,et al.  Molecular cloning of S‐protein, a link between complement, coagulation and cell‐substrate adhesion. , 1985, The EMBO journal.

[17]  J. Tschopp,et al.  Monoclonal Antibodies Recognizing a Neoantigen of Poly(C9) Detect the Human Terminal Complement Complex in Tissue and Plasma , 1985, Scandinavian journal of immunology.

[18]  J. Neuberger,et al.  Mononuclear cell complement receptor blockade in primary biliary cirrhosis. , 1985, Gut.

[19]  S. Bhakdi,et al.  Mechanism of complement cytolysis and the concept of channel-forming proteins. , 1984, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[20]  K. Whaley,et al.  Complement activation in chronic liver disease. , 1982, Clinical and experimental immunology.

[21]  R. Wiesner,et al.  Clinicopathologic features of the syndrome of primary sclerosing cholangitis , 1980 .

[22]  S. Bhakdi,et al.  Complement Lysis: the Ultrastructure and Orientation of the C5b‐9 Complex on Target Sheep Erythrocyte Membranes , 1978, Scandinavian journal of immunology.

[23]  A. Dalmasso,et al.  Localization of S protein and its relationship to the membrane attack complex of complement in renal tissue. , 1987, The American journal of pathology.

[24]  S. Lindgren,et al.  Complement Components and Activation in Primary Biliary Cirrhosis , 1984, Hepatology.

[25]  M. Frank,et al.  Primary Biliary Cirrhosis and the Complement System , 1979 .

[26]  E. Gjone,et al.  Humoral immune system activity in inflammatory bowel disease. , 1975, Scandinavian journal of gastroenterology.